Bernie Sanders Targets Novo Nordisk Over High U.S. Drug Prices

Senator Sanders calls for price cuts on Ozempic and Wegovy, citing a significant cost disparity compared to Europe.

Sanders urges Denmark's largest company, Novo Nordisk, to reduce prices for its diabetes and weight loss drugs.
The senator highlights the drugs' affordability in Europe versus the exorbitant costs in the U.S., which can reach $6,700 monthly.
Novo Nordisk's high pricing practices are criticized amidst a surge in demand and significant health benefits of the drugs.
Sanders’ campaign against drug prices includes public appeals in Denmark and direct challenges to Novo Nordisk's executives.
Despite price reductions in recent years, U.S. costs for Ozempic remain substantially higher than in other countries.